Apoptosis Regulator BAX Drugs Development Market Research Report 2021 – ResearchAndMarkets.com

DUBLIN – (COMMERCIAL THREAD)–The “Apoptosis Regulator BAX – Drugs In Development, 2021” drug pipelines was added to ResearchAndMarkets.com offer.

BAX Apoptosis Regulator (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – The BAX or bcl-2-like protein 4 apoptosis regulator is a protein encoded by the BAX gene.

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) The target constitutes nearly 8 molecules.

Of which around 3 molecules are developed by companies and the remainder by universities / institutes. The molecules developed by companies in Phase II and in Preclinical are respectively 1 and 2. Likewise, the portfolio of universities at the preclinical and discovery stages comprises respectively 3 and 2 molecules.

The report covers products from the therapeutic areas of Oncology, Cardiovascular, Central Nervous System and Ophthalmology, which include the indications Lung Cancer, Acute Ischemic Stroke, Acute Myeloid Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, Hepatocellular Carcinoma, Melanoma, Myocardial Infarction and Parkinson’s Disease.

The latest Apoptosis Regulator BAX – Drugs In Development report, 2021, provides comprehensive information on Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapies, complete with analysis by indications, stage of development, mechanism of development. action (MoA), route of administration (RoA) and type of molecule. It also reviews the main players involved in the development of targeted therapies of the apoptosis regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) with respective active and dormant or abandoned projects.

Scope

  • The report provides an overview of the global therapeutic landscape of the apoptosis regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX)

  • The report reviews targeted apoptosis regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) therapies under development by companies and universities / research institutes based on information from sources specific to business and industry.

  • The report covers the pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed milestones.

  • The report features descriptive drug profiles for products in the pipeline, including product description, descriptive MoA, R&D brief, licensing and collaboration details, and other development activities.

  • The report reviews the main players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapies and enlists all their major and minor projects

  • The report assesses targeted apoptosis regulator BAX therapies (Bcl 2 Like Protein 4 or BCL2L4 or BAX) based on mechanism of action (MoA), route of administration (RoA) and molecule type.

  • Report summarizes all dormant and abandoned pipeline projects

  • The report reviews the latest news and offerings related to BAX Apoptosis Regulator Targeted Therapies (Bcl 2 Like Protein 4 or BCL2L4 or BAX)

Discussed subjects :

introduction

BAX Apoptosis Regulator (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Overview

BAX apoptosis regulator (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Therapeutic development

  • Products under development by stage of development

  • Products under development by therapeutic area

  • Products in development by indication

  • Products in development by companies

  • Products under development by universities / institutes

BAX Apoptosis Regulator (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Therapeutic Evaluation

  • Assessment by mechanism of action

  • Assessment by administration

  • Evaluation by molecule type

BAX apoptosis regulator (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Companies involved in therapeutic development

  • Genervon Biopharmaceuticals LLC

  • Lytix Biopharma AS

  • Doctorate Biosciences

BAX Apoptosis Regulator (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Drug Profiles

CYD-211 – Drug Profile

  • Product Description

  • Action mechanism

  • R&D progress

GM-6 – Drug Profile

  • Product Description

  • Action mechanism

  • R&D progress

LTX-401 – Drug Profile

  • Product Description

  • Action mechanism

  • R&D progress

Small Molecule to Activate BAX Apoptosis Regulator for Lung Cancer – Drug Profile

  • Product Description

  • Action mechanism

  • R&D progress

Small Molecule to Activate BAX for Acute Myeloid Leukemia – Drug Profile

  • Product Description

  • Action mechanism

  • R&D progress

Small Molecule to Inhibit BAX for Myocardial Infarction – Drug Profile

  • Product Description

  • Action mechanism

  • R&D progress

Small Molecules to Inhibit BAX for Ophthalmology – Drug Profile

  • Product Description

  • Action mechanism

  • R&D progress

SMBA-1 – Drug Profile

  • Product Description

  • Action mechanism

  • R&D progress

BAX Apoptosis Regulator (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Dormant Products

BAX Apoptosis Regulator (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Product Development Milestones

appendix

For more information on this Drug Pipeline Report, visit https://www.researchandmarkets.com/r/eqpojn


Source link

About Michael Bill

Check Also

Hohenloher Landschwein – Lexology

In a recently published judgment, the Federal Court of Justice ruled on the relationship between …

Leave a Reply

Your email address will not be published. Required fields are marked *